Laboratory Co. of America (LH) Stock Forecast & Price Target

$215.77

+0.64 (+0.30%)

(As of 10/18/2024 ET)

Laboratory Co. of America - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
4

Buy
10

Based on 14 Wall Street analysts who have issued ratings for Laboratory Co. of America in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 4 have given a hold rating, and 10 have given a buy rating for LH.

Consensus Price Target

$251.85
16.72% Upside

According to the 14 analysts' twelve-month price targets for Laboratory Co. of America, the average price target is $251.85. The highest price target for LH is $282.00, while the lowest price target for LH is $230.00. The average price target represents a forecasted upside of 16.72% from the current price of $215.77.

LH Analyst Ratings Over Time

Type	Current Forecast 10/21/23 to 10/20/24	1 Month Ago 9/21/23 to 9/20/24	3 Months Ago 7/23/23 to 7/22/24	1 Year Ago 10/21/22 to 10/21/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	9 Buy rating(s)	11 Buy rating(s)	8 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$251.85	$251.27	$241.29	$244.55
Forecasted Upside	16.72% Upside	13.07% Upside	12.57% Upside	22.36% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Man behind OpenAI makes shocking new bet (Ad)

Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.

Check out our report right here.

LH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Laboratory Co. of America Stock vs. The Competition

Type	Laboratory Co. of America	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	16.72% Upside	13,587.63% Upside	6.19% Upside
News Sentiment Rating	Positive News See Recent LH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/16/2024	Barclays 3 of 5 stars		Lower Target	Equal Weight ➝ Equal Weight	$249.00 ➝ $234.00	+7.99%
10/1/2024	Piper Sandler 2 of 5 stars	D. Westenberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$235.00	+5.15%
9/24/2024	Evercore ISI 2 of 5 stars		Lower Target	In-Line ➝ In-Line	$250.00 ➝ $240.00	+8.83%
9/23/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$245.00 ➝ $265.00	+18.65%
9/20/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$278.00 ➝ $282.00	+25.56%
8/5/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$240.00 ➝ $260.00	+13.39%
Man behind OpenAI makes shocking new bet (Ad) Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously. Check out our report right here.
8/2/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$260.00 ➝ $270.00	+14.63%
8/2/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$220.00 ➝ $230.00	-2.35%
8/2/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$255.00 ➝ $275.00	+18.79%
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$261.00 ➝ $243.00	+25.49%
3/25/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$250.00	+17.23%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/26/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$260.00	+18.63%
10/31/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$257.00 ➝ $230.00	+16.07%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$210.00	+2.71%
8/14/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$290.00 ➝ $270.00	+23.85%
8/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$285.00 ➝ $260.00	+20.81%
8/2/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$247.41 ➝ $231.00	+8.14%
4/26/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$260.00 ➝ $235.00	+6.14%
10/27/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Brackmann Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:48 AM ET.

Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 15, 2024. Please send any questions or comments about these Laboratory Co. of America pros and cons to contact@marketbeat.com.

Laboratory Co. of America
Bull Case

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

Labcorp Holdings Inc. provides laboratory services through two segments, Diagnostics Laboratories and Biopharma Laboratory Services, offering a wide range of tests including blood chemistry analyses, urinalyses, blood cell counts, and more.

Laboratory Co. of America
Bear Case

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

Labcorp Holdings Inc. operates in a highly competitive industry with potential regulatory challenges and pricing pressures.

LH Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Laboratory Co. of America is $251.85, with a high forecast of $282.00 and a low forecast of $230.00.
: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last twelve months. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LH shares.
: According to analysts, Laboratory Co. of America's stock has a predicted upside of 16.72% based on their 12-month stock forecasts.
: Laboratory Co. of America has been rated by research analysts at Bank of America, Barclays, Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group, Piper Sandler, Robert W. Baird, Truist Financial, and UBS Group in the past 90 days.
: Analysts like Laboratory Co. of America less than other "medical" companies. The consensus rating score for Laboratory Co. of America is 2.71 while the average consensus rating score for "medical" companies is 2.79. Learn more on how LH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Watch this before it gets removed (Ad)

If you missed it, my emergency election broadcast is now available - but will be removed on Monday at midnight.

Click here to watch it now.

This page (NYSE:LH) was last updated on 10/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Laboratory Co. of America (LH) Stock Forecast & Price Target